Compare AbbVie Inc (ABBV) vs SkyWest Inc (SKYW) Price & Performance

AbbVie (ABBV) trades at $247.91, up 0.76% on the day, with strong technical momentum as the stock approaches resistance near $249. The company demonstrates solid fundamentals with Q2 2026 EPS beating expectations at $3.65 versus $3.61, driven by robust immunology portfolio growth from Skyrizi and Rinvoq offsetting Humira declines. Revenue reached $61.16B in 2025 with a 71.48% gross margin, though net income margin compressed to 9.8%. Recent positive Phase 2 ovarian cancer data and institutional accumulation signal confidence in the pipeline.

Outlook remains positive with analyst consensus target of $281.33 (13.5% upside) and 71% buy ratings, though elevated P/E of 70.05 reflects growth expectations. Key risks include patent cliffs in the 2030s, competitive pressures, and regulatory uncertainties from drug pricing lawsuits. The dividend aristocrat offers income stability with recent $1.73 payout, but investors should monitor execution of oncology pipeline and debt levels at 50.4% of assets.

SkyWest (SKYW) trades at $111.84, down 1.41% on the day, with a bullish technical signal supported by moving averages and a consensus analyst buy rating. Recent Q2 2026 earnings missed estimates at $2.54 EPS versus $2.70 expected, but revenue trends show growth to $4.2B in 2026. The stock benefits from strong profitability with a 9.78% net margin and attractive valuation metrics, including a P/E of 10.69. Key developments include executive stock sales and a 7.7% post-earnings rally noted by Zacks on July 27, 2026.

Outlook remains positive due to undervaluation and fleet expansion, but risks include fuel cost volatility from Iran war impacts (New York Post, July 7, 2026) and insider selling. The consensus price target of $109.33 suggests limited upside, with execution on earnings beats being critical for further gains.